Clinical resource
Head and neck oropharynx squamous cell carcinoma definitive EBRT with or without chemotherapy (eviQ ID 5049)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for definitive radiotherapy of oropharyngeal squamous cell carcinoma, with or without concurrent chemotherapy. It replaces the earlier separate radiotherapy-alone (740) and chemoradiation (3362) protocols. DoseLab's head and neck constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each. The same organ table appears in eviQ's oral cavity, larynx/hypopharynx, early glottic, nasopharynx and post-operative head and neck protocols.
Why this is useful
The organ-at-risk table behind DoseLab's head and neck constraint table, with the primary study credited for each value.
Reference details
- Title
- Head and neck oropharynx squamous cell carcinoma definitive EBRT with or without chemotherapy (eviQ ID 5049)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 5049
- Version
- v.1 — first approved 30 April 2026; review due 30 June 2030
- Year
- 2026
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Dose Constraints, Protocols
- Fractionation context
- 70 Gy / 35 fx SIB (63 and 56 Gy dose levels); accelerated 6 fractions per week option
- Last reviewed by DoseLab
- 2026-09-24